Omnix Medical bags €10.8m from EIC Accerator Fund
Israel’s Omnix Medical has been granted €10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Germany orders antibody therapies from USA
Germany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.
Servier and MiNA Therapeutics sign €220m deal
French Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
LSP leads €21m round into Neurent Medical
Irish life sciences company Neurent Medical has closed a €21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
Janssen presents one-shot COVID-19 vaccine data
J&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.
Automate your DNA variant library synthesis and reduce turnaround time from weeks and months to days and hours
The BioXp system is the world’s only automated platform for on-demand DNA assembly and amplification.
German researchers find reason for remdesivir’s inefficiency
German Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.
LSP reports first closing of dementia fund
European life sciences investors LSP has closed a new fund to fight dementia at €50m.
Valneva in talks with EU about 60 million vaccine doses
French Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
Immunocore bags US$75m in Series C round
Immuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round.